Möchten Sie immer auf dem neuesten Stand bleiben?

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to...

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Prime Dividend Corp. (The "Company") declares its monthly distribution of $0.09342 for each Class A share and $0.05667 for each Preferred share....

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (“TG” or “the Company”), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of...

Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594...

Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its...

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S....

TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Prime Dividend Corp. (The "Company") declares its monthly distribution of $0.08225 for each Class A share and $0.05875 for each Preferred share....

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479),...